Quest Diagnostics reported second quarter 2026 revenues of $3.04 billion, a 10.2% increase from 2025, and adjusted diluted EPS of $3.12, up 19.1% year-over-year. The company raised its full year 2026 guidance, now expecting revenues between $11.95 billion and $12.05 billion and adjusted diluted EPS between $11.05 and $11.25. Quest Diagnostics is a provider of diagnostic information services.

Quest Diagnostics announced the results of its 2026 Annual Meeting, where stockholders elected all director nominees and approved executive compensation and the appointment of PricewaterhouseCoopers. A stockholder proposal to mandate an independent board chairman was defeated, receiving 23,999,636 votes in favor and 69,792,819 votes against.

Quest Diagnostics Incorporated issued $500 million in aggregate principal amount of 5.000% senior notes due 2036. The notes are senior unsecured obligations of the company and are scheduled to mature on June 30, 2036.

Quest Diagnostics Incorporated has priced a $500 million public offering of 5.000% senior notes due 2036. The company intends to use the net proceeds for general corporate purposes, which may include the repayment of $500 million in 3.45% senior notes maturing on June 1, 2026.

Quest Diagnostics Incorporated has elected Timothy Wentworth, the former CEO of Walgreens Boots Alliance, to its Board of Directors. Mr. Wentworth will serve on the Compensation and Leadership Development and Quality and Compliance committees and received a prorated one-time grant of restricted share units valued at approximately $43,000.